Guidelines for the first line management of classical Hodgkin lymphoma

British Journal of Haematology

Volumn 166, Issue 1, 2014, Pages 34-49

  Follows, George A ^a   Ardeshna, Kirit M ^b   Barrington, Sally F ^c   Culligan, Dominic J ^d   Hoskin, Peter J ^e   Linch, David ^b,f   Sadullah, Shalal ^g   Williams, Michael V ^h   Wimperis, Jennifer Z ⁱ  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e MOUNT VERNON CANCER CENTRE   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g JAMES PAGET UNIVERSITY HOSPITAL   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Hodgkin; Hodgkin lymphoma; Radiotherapy; Treatment

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; GEMCITABINE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; BLOOD EXAMINATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER TRANSPLANTATION; CARDIOVASCULAR DISEASE; CLASSICAL HODGKIN LYMPHOMA; COMORBIDITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COUGHING; CRACKLE; CRYOPRESERVATION; DIABETES MELLITUS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FOLLOW UP; HEALTH CARE QUALITY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; INFERTILITY; INTERNATIONAL PROGNOSTIC SCORE; LABORATORY DIAGNOSIS; LUNG DISEASE; LUNG FIBROSIS; LUNG TOXICITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NECK; PELVIS; PRACTICE GUIDELINE; PREGNANCY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RADIATION INJURY; RADIATION ONCOLOGIST; RISK ASSESSMENT; SCORING SYSTEM; SECOND CANCER; SEROLOGY;

CHEMOTHERAPY; HODGKIN; HODGKIN LYMPHOMA; RADIOTHERAPY; TREATMENT;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HODGKIN DISEASE; HUMANS; LONG-TERM CARE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84902345732     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12878     Document Type: Article

References (110)

1. Aleman, B.M., Raemaekers, J.M., Tirelli, U., Bortolus, R., van't Veer, M.B., Lybeert, M.L., Keuning, J.J., Carde, P., Girinsky, T., van der Maazen, R.W., Tomsic, R., Vovk, M., van Hoof, A., Demeestere, G., Lugtenburg, P.J., Thomas, J., Schroyens, W., De Boeck, K., Baars, J.W., Kluin-Nelemans, J.C., Carrie, C., Aoudjhane, M., Bron, D., Eghbali, H., Smit, W.G., Meerwaldt, J.H., Hagenbeek, A., Pinna, A. & Henry-Amar, M. (2003) Involved-field radiotherapy for advanced Hodgkin's lymphoma. New England Journal of Medicine, 348, 2396-2406.
2. Andre, M.P., Reman, O., Federico, M., Girinski, T., Brice, P., Brusamolino, E., Ferme, C., van der Maazen, R., Bellei, M., Sebban, C., Morschhauser, F., Lugtenburg, E., Stamatoulas, A., Fortpied, C., Meignan, M., Versari, A., Hutchings, M. & Raemaekers, J. (2012) Interim analysis of the randomized Eortc/Lysa/Fil intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts), 120, 549.
3. Anselmo, A.P., Cavalieri, E., Enrici, R.M., Pescarmona, E., Guerrisi, V., Paesano, R., Pachi, A. & Mandelli, F. (1999) Hodgkin's disease during pregnancy: diagnostic and therapeutic management. Fetal Diagnosis and Therapy, 14, 102-105.
4. Bachanova, V. & Connors, J.M. (2008) How is Hodgkin lymphoma in pregnancy best treated? ASH evidence-based review 2008. American Society of Haematology Education Program, 33-34.
5. Baglin, T.P., Joysey, V.C., Horsford, J., Johnson, R.T., Broadbent, V. & Marcus, R.E. (1992) Transfusion-associated graft-versus-host disease in patients with Hodgkin's disease and T cell lymphoma. Transfusion Medicine, 2, 195-199.
6. Ballova, V., Ruffer, J.U., Haverkamp, H., Pfistner, B., Muller-Hermelink, H.K., Duhmke, E., Worst, P., Wilhelmy, M., Naumann, R., Hentrich, M., Eich, H.T., Josting, A., Loffler, M., Diehl, V. & Engert, A. (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Annals of Oncology, 16, 124-131.
7. Barrington, S.F. & O'Doherty, M.J. (2003) Limitations of PET for imaging lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 30(Suppl. 1), S117-S127.
8. Barrington, S.F., Qian, W., Somer, E.J., Franceschetto, A., Bagni, B., Brun, E., Almquist, H., Loft, A., Hojgaard, L., Federico, M., Gallamini, A., Smith, P., Johnson, P., Radford, J. & O'Doherty, M.J. (2010) Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 37, 1824-1833.
9. Barrington, S.F., Mackewn, J.E., Schleyer, P., Marsden, P.K., Mikhaeel, N.G., Qian, W., Mouncey, P., Patrick, P., Popova, B., Johnson, P., Radford, J. & O'Doherty, M.J. (2011) Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Annals of Oncology, 22, 739-745.
10. Baxi, S.S. & Matasar, M.J. (2010) State-of-the-art issues in Hodgkin's lymphoma survivorship. Current Oncology Reports, 12, 366-373.
11. Behringer, K., Breuer, K., Reineke, T., May, M., Nogova, L., Klimm, B., Schmitz, T., Wildt, L., Diehl, V. & Engert, A. (2005) Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology, 23, 7555-7564.
12. Behringer, K., Thielen, I., Mueller, H., Goergen, H., Eibl, A.D., Rosenbrock, J., Halbsguth, T., Eichenauer, D.A., Fuchs, M., Reiners, K.S., Renno, J.H., van der Ven, K., Kuehr, M., von Wolff, M., Diehl, V., Engert, A. & Borchmann, P. (2012) Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology, 23, 1818-1825.
13. Behringer, K., Mueller, H., Goergen, H., Thielen, I., Eibl, A.D., Stumpf, V., Wessels, C., Wiehlputz, M., Rosenbrock, J., Halbsguth, T., Reiners, K.S., Schober, T., Renno, J.H., von Wolff, M., van der Ven, K., Kuehr, M., Fuchs, M., Diehl, V., Engert, A. & Borchmann, P. (2013) Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology, 31, 231-239.
14. Bhatia, S., Yasui, Y., Robison, L.L., Birch, J.M., Bogue, M.K., Diller, L., DeLaat, C., Fossati-Bellani, F., Morgan, E., Oberlin, O., Reaman, G., Ruymann, F.B., Tersak, J. & Meadows, A.T. (2003) High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. Journal of Clinical Oncology, 21, 4386-4394.
15. Biggi, A., Gallamini, A., Chauvie, S., Hutchings, M., Kostakoglu, L., Gregianin, M., Meignan, M., Malkowski, B., Hofman, M.S. & Barrington, S.F. (2013) International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. Journal of Nuclear Medicine, 54, 683-690.
16. Boellaard, R., O'Doherty, M.J., Weber, W.A., Mottaghy, F.M., Lonsdale, M.N., Stroobants, S.G., Oyen, W.J., Kotzerke, J., Hoekstra, O.S., Pruim, J., Marsden, P.K., Tatsch, K., Hoekstra, C.J., Visser, E.P., Arends, B., Verzijlbergen, F.J., Zijlstra, J.M., Comans, E.F., Lammertsma, A.A., Paans, A.M., Willemsen, A.T., Beyer, T., Bockisch, A., Schaefer-Prokop, C., Delbeke, D., Baum, R.P., Chiti, A. & Krause, B.J. (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 37, 181-200.
17. Boll, B., Bredenfeld, H., Gorgen, H., Halbsguth, T., Eich, H.T., Soekler, M., Markova, J., Keller, U., Graeven, U., Kremers, S., Geissler, M., Trenn, G., Fuchs, M., von Tresckow, B., Eichenauer, D.A., Borchmann, P. & Engert, A. (2011) Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood, 118, 6292-6298.
18. Boll, B., Gorgen, H., Fuchs, M., Pluetschow, A., Eich, H.T., Bargetzi, M.J., Weidmann, E., Junghanss, C., Greil, R., Scherpe, A., Schmalz, O., Eichenauer, D.A., von Tresckow, B., Rothe, A., Diehl, V., Engert, A. & Borchmann, P. (2013) ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. Journal of Clinical Oncology, 31, 1522-1529.
19. Borchmann, P., Diehl, V. & Engert, A. (2011) ABVD versus BEACOPP for Hodgkin's lymphoma. New England Journal of Medicine, 365, 1545-1546; author reply 1546.
20. Cancer Research UK (2010) Cancer Research UK Hodgkin Lymphoma Incidence Statistics. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/hodgkinslymphoma/incidence/uk-hodgkins-lymphoma-incidence-statistics. [Accessed May 28, 2013].
21. Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., Green, M.R., Gottlieb, A. & Peterson, B.A. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New England Journal of Medicine, 327, 1478-1484.
22. Carde, P.P., Karrasch, M., Fortpied, C., Brice, P., Khaled, H.M., Caillot, D., Gaillard, I., Bologna, S., Ferme, C., Lugtenburg, P., Morschhauser, F., Aurer, I., Coiffier, B., Cantin, G., Seftel, M.D., Wolf, M., Glimelius, B., Sureda, A. & Mounier, N. (2012) ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): first results of EORTC 20012 intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30(15 Suppl), 8002.
23. Cardonick, E. & Iacobucci, A. (2004) Use of chemotherapy during human pregnancy. The Lancet Oncology, 5, 283-291.
24. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
25. Corazzelli, G., Russo, F. & Pinto, A. (2011) ABVD versus BEACOPP for Hodgkin's lymphoma. New England Journal of Medicine, 365, 1545; author reply 1546.
26. Darabi, K., Sieber, M., Chaitowitz, M., Braitman, L.E., Tester, W. & Diehl, V. (2005) Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: a retrospective review of 1114 patients. Leukemia & Lymphoma, 46, 1715-1720.
27. De Bruin, M.L., Huisbrink, J., Hauptmann, M., Kuenen, M.A., Ouwens, G.M., van't Veer, M.B., Aleman, B.M. & van Leeuwen, F.E. (2008) Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood, 111, 101-108.
28. Duggan, D.B., Petroni, G.R., Johnson, J.L., Glick, J.H., Fisher, R.I., Connors, J.M., Canellos, G.P. & Peterson, B.A. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. Journal of Clinical Oncology, 21, 607-614.
29. Eich, H.T., Diehl, V., Gorgen, H., Pabst, T., Markova, J., Debus, J., Ho, A., Dorken, B., Rank, A., Grosu, A.L., Wiegel, T., Karstens, J.H., Greil, R., Willich, N., Schmidberger, H., Dohner, H., Borchmann, P., Muller-Hermelink, H.K., Muller, R.P. & Engert, A. (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Journal of Clinical Oncology, 28, 4199-4206.
30. El-Galaly, T.C., d'Amore, F., Mylam, K.J., de Nully Brown, P., Bogsted, M., Bukh, A., Specht, L., Loft, A., Iyer, V., Hjorthaug, K., Nielsen, A.L., Christiansen, I., Madsen, C., Johnsen, H.E. & Hutchings, M. (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. Journal of Clinical Oncology, 30, 4508-4514.
31. Engert, A., Franklin, J., Eich, H.T., Brillant, C., Sehlen, S., Cartoni, C., Herrmann, R., Pfreundschuh, M., Sieber, M., Tesch, H., Franke, A., Koch, P., de Wit, M., Paulus, U., Hasenclever, D., Loeffler, M., Muller, R.P., Muller-Hermelink, H.K., Duhmke, E. & Diehl, V. (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Journal of Clinical Oncology, 25, 3495-3502.
32. Engert, A., Diehl, V., Franklin, J., Lohri, A., Dorken, B., Ludwig, W.D., Koch, P., Hanel, M., Pfreundschuh, M., Wilhelm, M., Trumper, L., Aulitzky, W.E., Bentz, M., Rummel, M., Sezer, O., Muller-Hermelink, H.K., Hasenclever, D. & Loffler, M. (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. Journal of Clinical Oncology, 27, 4548-4554.
33. Engert, A., Plutschow, A., Eich, H.T., Lohri, A., Dorken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K.C., Wilhelm, M., Debus, J., Eble, M.J., Sokler, M., Ho, A., Rank, A., Ganser, A., Trumper, L., Bokemeyer, C., Kirchner, H., Schubert, J., Kral, Z., Fuchs, M., Muller-Hermelink, H.K., Muller, R.P. & Diehl, V. (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. New England Journal of Medicine, 363, 640-652.
34. Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Kral, Z., Fuchs, M., Hallek, M., Kanz, L., Dohner, H., Dorken, B., Engel, N., Topp, M., Klutmann, S., Amthauer, H., Bockisch, A., Kluge, R., Kratochwil, C., Schober, O., Greil, R., Andreesen, R., Kneba, M., Pfreundschuh, M., Stein, H., Eich, H.T., Muller, R.P., Dietlein, M., Borchmann, P. & Diehl, V. (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet, 379, 1791-1799.
35. Evens, A.M., Cilley, J., Ortiz, T., Gounder, M., Hou, N., Rademaker, A., Miyata, S., Catsaros, K., Augustyniak, C., Bennett, C.L., Tallman, M.S., Variakojis, D., Winter, J.N. & Gordon, L.I. (2007) G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. British Journal of Haematology, 137, 545-552.
36. Evens, A.M., Sweetenham, J.W. & Horning, S.J. (2008) Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology, 22, 1369-1379.
37. Evens, A.M., Advani, R., Lossos, I.S., Press, O.W., Vose, J.M., Hernandez-Ilizaliturri, F.J., Robinson, B.K., Otis, S., Dagan, L.N., Abdallah, R., Kroll, A., Sandoval, J., Yarber, J.L., Foyil, K.V., Parker, L.M., Gordon, L.I., Leonard, J.P., Habermann, T.M. & Bartlett, N.L. (2011) Lymphoma in pregnancy: excellent fetal outcomes and maternal survival in a large multicenter analysis. Blood (ASH Annual Meeting Abstracts), 118, 94.
38. Evens, A.M., Helenowski, I., Ramsdale, E., Nabhan, C., Karmali, R., Hanson, B., Parsons, B., Smith, S., Larsen, A., McKoy, J.M., Jovanovic, B., Gregory, S., Gordon, L.I. & Smith, S.M. (2012) A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood, 119, 692-695.
39. Evens, A.M., Hong, F., Gordon, L.I., Fisher, R.I., Bartlett, N.L., Connors, J.M., Gascoyne, R.D., Wagner, H., Gospodarowicz, M., Cheson, B.D., Stiff, P.J., Advani, R., Miller, T.P., Hoppe, R.T., Kahl, B.S. & Horning, S.J. (2013) The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. British Journal of Haematology, 161, 76-86.
40. Favier, O., Heutte, N., Stamatoullas-Bastard, A., Carde, P., van't Veer, M.B., Aleman, B.M., Noordijk, E.M., Thomas, J., Ferme, C. & Henry-Amar, M. (2009) Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer, 115, 1680-1691.
41. Federico, M., Luminari, S., Iannitto, E., Polimeno, G., Marcheselli, L., Montanini, A., La Sala, A., Merli, F., Stelitano, C., Pozzi, S., Scalone, R., Di Renzo, N., Musto, P., Baldini, L., Cervetti, G., Angrilli, F., Mazza, P., Brugiatelli, M. & Gobbi, P.G. (2009) ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology, 27, 805-811.
42. Ferme, C., Eghbali, H., Meerwaldt, J.H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., van't Veer, M.B., Walewski, J.A., Lederlin, P., Tirelli, U., Carde, P., Van den Neste, E., Gyan, E., Monconduit, M., Divine, M., Raemaekers, J.M., Salles, G., Noordijk, E.M., Creemers, G.J., Gabarre, J., Hagenbeek, A., Reman, O., Blanc, M., Thomas, J., Vie, B., Kluin-Nelemans, J.C., Viseu, F., Baars, J.W., Poortmans, P., Lugtenburg, P.J., Carrie, C., Jaubert, J. & Henry-Amar, M. (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. New England Journal of Medicine, 357, 1916-1927.
43. Franklin, J.G., Paus, M.D., Pluetschow, A. & Specht, L. (2005) Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. The Cochrane Database of Systematic Reviews, CD003187.
44. Franklin, J., Pluetschow, A., Paus, M., Specht, L., Anselmo, A.P., Aviles, A., Biti, G., Bogatyreva, T., Bonadonna, G., Brillant, C., Cavalieri, E., Diehl, V., Eghbali, H., Ferme, C., Henry-Amar, M., Hoppe, R., Howard, S., Meyer, R., Niedzwiecki, D., Pavlovsky, S., Radford, J., Raemaekers, J., Ryder, D., Schiller, P., Shakhtarina, S., Valagussa, P., Wilimas, J. & Yahalom, J. (2006) Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Annals of Oncology, 17, 1749-1760.
45. Furth, C., Amthauer, H., Hautzel, H., Steffen, I.G., Ruf, J., Schiefer, J., Schonberger, S., Henze, G., Grandt, R., Hundsdoerfer, P., Dietlein, M. & Kobe, C. (2011) Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma-results for dedicated assessment criteria in a blinded dual-centre read. Annals of Oncology, 22, 1198-1203.
46. Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., Biggi, A., Vitolo, U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I. & Levis, A. (2007) Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology, 25, 3746-3752.
47. Gallamini, A., Patti, C., Viviani, S., Rossi, A., Fiore, F., Di Raimondo, F., Cantonetti, M., Stelitano, C., Feldman, T., Gavarotti, P., Sorasio, R., Mule, A., Leone, M., Rambaldi, A., Biggi, A., Barrington, S., Fallanca, F., Ficola, U., Chauvie, S. & Gianni, A.M. (2011) Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. British Journal of Haematology, 152, 551-560.
48. Gallamini, A., Rossi, A., Patti, C., Picardi, M., Di Raimondo, F., Cantonetti, M., La Nasa, G., Viviani, S., Bolis, S., Trentin, L., Olivieri, A., Zoli, V., Biggi, A., Chauvie, S., Fiore, F., Cavallo, A., Prosperini, G., Marchioli, R., Parvis, G., Zanotti, R., Gavarotti, P., Dodero, A., Schiavotto, C., Ciceri, F., Avigdor, A., Mule, A., Tarella, C., Gianni, A.M. & Rambaldi, A. (2012) Early treatment intensification in advanced-stage high-risk Hodgkin lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses - first interim analysis of the GITIL/FIL HD0607 clinical trial. Blood (ASH Annual Meeting Abstracts), 120, 550.
49. Girinsky, T., Specht, L., Ghalibafian, M., Edeline, V., Bonniaud, G., Van Der Maazen, R., Aleman, B., Paumier, A., Meijnders, P., Lievens, Y., Noordijk, E. & Poortmans, P. (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiotherapy and Oncology, 88, 202-210.
50. Halbsguth, T.V., Nogova, L., Mueller, H., Sieniawski, M., Eichenauer, D.A., Schober, T., Nisters-Backes, H., Borchmann, P., Diehl, V., Engert, A. & Josting, A. (2010) Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood, 116, 2026-2032.
51. Hasenclever, D. & Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. New England Journal of Medicine, 339, 1506-1514.
52. Hay, A.E., Klimm, B., Chen, B.E., Goergen, H., Shepherd, L.E., Fuchs, M., Gospodarowicz, M., Borchmann, P., Connors, J.M., Markova, J., Crump, M., Lohri, A., Winter, J.N., Dorken, B., Pearcey, R.G., Diehl, V., Horning, S.J., Eich, H.T., Engert, A. & Meyer, R.M. (2012) Treatment of stage I-II A non-bulky Hodgkin's lymphoma (HL): an individual patient-data comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 combined-modality therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD alone. Blood (ASH Annual Meeting Abstracts), 120, 548.
53. Hodgson, D.C., Pintilie, M., Gitterman, L., Dewitt, B., Buckley, C.A., Ahmed, S., Smith, K., Schwartz, A., Tsang, R.W., Crump, M., Wells, W., Sun, A. & Gospodarowicz, M.K. (2007a) Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematological Oncology, 25, 11-15.
54. Hodgson, D.C., Gilbert, E.S., Dores, G.M., Schonfeld, S.J., Lynch, C.F., Storm, H., Hall, P., Langmark, F., Pukkala, E., Andersson, M., Kaijser, M., Joensuu, H., Fossa, S.D. & Travis, L.B. (2007b) Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. Journal of Clinical Oncology, 25, 1489-1497.
55. Hoskin, P.J., Lowry, L., Horwich, A., Jack, A., Mead, B., Hancock, B.W., Smith, P., Qian, W., Patrick, P., Popova, B., Pettitt, A., Cunningham, D., Pettengell, R., Sweetenham, J., Linch, D. & Johnson, P.W. (2009) Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. Journal of Clinical Oncology, 27, 5390-5396.
56. Hoskin, P.J., Diez, P., Williams, M., Lucraft, H. & Bayne, M. (2013) Recommendations for the use of radiotherapy in nodal lymphoma. Clinical Oncology, 25, 49-58.
57. Howell, S.J., Searle, C., Goode, V., Gardener, T., Linton, K., Cowan, R.A., Harris, M.A., Hopwood, P., Swindell, R., Norman, A., Kennedy, J., Howell, A., Wardley, A.M. & Radford, J.A. (2009) The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. British Journal of Cancer, 101, 582-588.
58. Hutchings, M., Mikhaeel, N.G., Fields, P.A., Nunan, T. & Timothy, A.R. (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Annals of Oncology, 16, 1160-1168.
59. Johnson, P.W., Radford, J.A., Cullen, M.H., Sydes, M.R., Walewski, J., Jack, A.S., MacLennan, K.A., Stenning, S.P., Clawson, S., Smith, P., Ryder, D. & Hancock, B.W. (2005) Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Journal of Clinical Oncology, 23, 9208-9218.
60. Johnson, P., Federico, M., Fossa, A., O'Doherty, M., Roberts, T., Stevens, L., Smith, P., Kirkwood, A., Anghel, G., Trotman, J., Berkahn, L., D' Amore, F., Enblad, G., Luminari, S., Viney, Z., Radford, J. & Barrington, S. (2013) Responses and chemotherapy dose adjustment determined by PET-CT imaging: first results from the international response adapted therapy in advanced Hodgkin lymphoma (RATHL) study. Hematological Oncology, 31 (Suppl. 1), abstract 126.
61. Juweid, M.E., Stroobants, S., Hoekstra, O.S., Mottaghy, F.M., Dietlein, M., Guermazi, A., Wiseman, G.A., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R.J., Weber, W.A., Reske, S.N., Schwaiger, M., Schwartz, L.H., Zijlstra, J.M., Siegel, B.A. & Cheson, B.D. (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Journal of Clinical Oncology, 25, 571-578.
62. Kaye, S.B., Mead, G.M., Fossa, S., Cullen, M., deWit, R., Bodrogi, I., van Groeningen, C., Sylvester, R., Collette, L., Stenning, S., De Prijck, L., Lallemand, E. & deMulder, P. (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. Journal of Clinical Oncology, 16, 692-701.
63. Kelly, K.M., Sposto, R., Hutchinson, R., Massey, V., McCarten, K., Perkins, S., Lones, M., Villaluna, D. & Weiner, M. (2011) BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood, 117, 2596-2603.
64. Kuppers, R., Engert, A. & Hansmann, M.L. (2012) Hodgkin lymphoma. The Journal of Clinical Investigation, 122, 3439-3447.
65. Le Roux, P.Y., Gastinne, T., Le Gouill, S., Nowak, E., Bodet-Milin, C., Querellou, S., Mahe, B., Dubruille, V., Blin, N., Salaun, P.Y. & Bodere-Kraeber, F. (2011) Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. European Journal of Nuclear Medicine and Molecular Imaging, 38, 1064-1071.
66. Levis, A., Pietrasanta, D., Godio, L., Vitolo, U., Ciravegna, G., Di Vito, F., Gavarotti, P., Guglielmelli, T., Orsucci, L., Raviolo, E., Rota Scalabrini, D., Salvi, F., Tonso, A., Aglietta, M., Boccadoro, M., Gallamini, A., Saglio, G., Scassa, E. & Gallo, E. (2004a) A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. Clinical Lymphoma, 5, 50-55.
67. Levis, A., Anselmo, A.P., Ambrosetti, A., Adamo, F., Bertini, M., Cavalieri, E., Gavarotti, P., Genua, A., Liberati, M., Pavone, V., Pietrasanta, D., Ricetti, M.M., Scalabrini, D.R., Salvi, F., Vitolo, U., Angelucci, E., Boccadoro, M., Gallo, E. & Mandelli, F. (2004b) VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Annals of Oncology, 15, 123-128.
68. Levy, R. & Kaplan, H.S. (1974) Impaired lymphocyte function in untreated Hodgkin's disease. New England Journal of Medicine, 290, 181-186.
69. Loren, A.W., Mangu, P.B., Beck, L.N., Brennan, L., Magdalinski, A.J., Partridge, A.H., Quinn, G., Wallace, W.H. & Oktay, K. (2013) Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update. Journal of Clinical Oncology, 31, 2500-2510.
70. Martin, W.G., Ristow, K.M., Habermann, T.M., Colgan, J.P., Witzig, T.E. & Ansell, S.M. (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 7614-7620.
71. Mauch, P.M., Kalish, L.A., Kadin, M., Coleman, C.N., Osteen, R. & Hellman, S. (1993) Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer, 71, 2062-2071.
72. Meadows, A.T., Friedman, D.L., Neglia, J.P., Mertens, A.C., Donaldson, S.S., Stovall, M., Hammond, S., Yasui, Y. & Inskip, P.D. (2009) Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. Journal of Clinical Oncology, 27, 2356-2362.
73. Meyer, R.M., Gospodarowicz, M.K., Connors, J.M., Pearcey, R.G., Bezjak, A., Wells, W.A., Burns, B.F., Winter, J.N., Horning, S.J., Dar, A.R., Djurfeldt, M.S., Ding, K. & Shepherd, L.E. (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 23, 4634-4642.
74. Meyer, R.M., Gospodarowicz, M.K., Connors, J.M., Pearcey, R.G., Wells, W.A., Winter, J.N., Horning, S.J., Dar, A.R., Shustik, C., Stewart, D.A., Crump, M., Djurfeldt, M.S., Chen, B.E. & Shepherd, L.E. (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. New England Journal of Medicine, 366, 399-408.
75. Milano, M.T., Li, H., Gail, M.H., Constine, L.S. & Travis, L.B. (2010) Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. Journal of Clinical Oncology, 28, 5088-5096.
76. Montoto, S., Shaw, K., Okosun, J., Gandhi, S., Fields, P., Wilson, A., Shanyinde, M., Cwynarski, K., Marcus, R., de Vos, J., Young, A.M., Tenant-Flowers, M., Orkin, C., Johnson, M., Chilton, D., Gribben, J.G. & Bower, M. (2012) HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. Journal of Clinical Oncology, 30, 4111-4116.
77. Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D. & Linet, M.S. (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood, 107, 265-276.
78. Nangalia, J., Smith, H. & Wimperis, J.Z. (2008) Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support. Leukemia & Lymphoma, 49, 1530-1536.
79. Ng, A.K., Bernardo, M.P., Weller, E., Backstrand, K.H., Silver, B., Marcus, K.C., Tarbell, N.J., Friedberg, J., Canellos, G.P. & Mauch, P.M. (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. Journal of Clinical Oncology, 20, 2101-2108.
80. Nichols, C.R., Catalano, P.J., Crawford, E.D., Vogelzang, N.J., Einhorn, L.H. & Loehrer, P.J. (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 16, 1287-1293.
81. Noordijk, E.M., Carde, P., Dupouy, N., Hagenbeek, A., Krol, A.D., Kluin-Nelemans, J.C., Tirelli, U., Monconduit, M., Thomas, J., Eghbali, H., Aleman, B.M., Bosq, J., Vovk, M., Verschueren, T.A., Peny, A.M., Girinsky, T., Raemaekers, J.M. & Henry-Amar, M. (2006) Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. Journal of Clinical Oncology, 24, 3128-3135.
82. O'Sullivan, J.M., Huddart, R.A., Norman, A.R., Nicholls, J., Dearnaley, D.P. & Horwich, A. (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Annals of Oncology, 14, 91-96.
83. Patel, V., Buckstein, M., Perini, R., Hill-Kayser, C., Svoboda, J. & Plastaras, J.P. (2013) Computed tomography and positron emission tomography/computed tomography surveillance after combined modality treatment of supradiaphragmatic Hodgkin lymphoma: a clinical and economic perspective. Leukemia & Lymphoma, 54, 2168-2176.
84. Proctor, S.J., Wilkinson, J. & Sieniawski, M. (2009) Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Critical Reviews in Oncology/Hematology, 71, 222-232.
85. Proctor, S.J., Wilkinson, J., Jones, G., Watson, G.C., Lucraft, H.H., Mainou-Fowler, T., Culligan, D., Galloway, M.J., Wood, K.M., McNally, R.J., James, P.W. & Goodlad, J.R. (2012) Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood, 119, 6005-6015.
86. Quarles van Ufford, H., Hoekstra, O., de Haas, M., Fijnheer, R., Wittebol, S., Tieks, B., Kramer, M. & de Klerk, J. (2010) On the added value of baseline FDG-PET in malignant lymphoma. Molecular Imaging and Biology, 12, 225-232.
87. Radford, J., Barrington, S., Counsell, N., Pettengell, R., Johnson, P., Wimperis, J., Coltart, S., Culligan, D., Lister, A., Bessell, E., Kruger, A., Popova, B., Hancock, B., Hoskin, P., Illidge, T. & O'Doherty, M. (2012) Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID Trial. Blood (ASH Annual Meeting Abstracts), 120, 547.
88. Shenoy, P., Maggioncalda, A., Malik, N. & Flowers, C.R. (2011) Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States. Advances in Hematology, 2011, 725219.
89. Sieniawski, M., Reineke, T., Nogova, L., Josting, A., Pfistner, B., Diehl, V. & Engert, A. (2008) Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood, 111, 71-76.
90. Sleijfer, S. (2001) Bleomycin-induced pneumonitis. Chest, 120, 617-624.
91. Spaepen, K., Stroobants, S., Dupont, P., Bormans, G., Balzarini, J., Verhoef, G., Mortelmans, L., Vandenberghe, P. & De Wolf-Peeters, C. (2003) [(18)F] FDG PET monitoring of tumour response to chemotherapy: does [(18)F] FDG uptake correlate with the viable tumour cell fraction? European Journal of Nuclear Medicine and Molecular Imaging, 30, 682-688.
92. Specht, L., Yahalom, J., Illidge, T., Berthelsen, A.K., Constine, L.S., Eich, H.T., Girinsky, T., Hoppe, R.T., Mauch, P., Mikhaeel, N.G. & Ng, A. (2013) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology Biology Physics, doi: 10.1016/j.ijrobp.2013.05.005.
93. Stark, G.L., Wood, K.M., Jack, F., Angus, B., Proctor, S.J. & Taylor, P.R. (2002) Hodgkin's disease in the elderly: a population-based study. British Journal of Haematology, 119, 432-440.
94. Steidl, C., Connors, J.M. & Gascoyne, R.D. (2011) Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. Journal of Clinical Oncology, 29, 1812-1826.
95. Swerdlow, A.J., Higgins, C.D., Smith, P., Cunningham, D., Hancock, B.W., Horwich, A., Hoskin, P.J., Lister, A., Radford, J.A., Rohatiner, A.Z. & Linch, D.C. (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. Journal of the National Cancer Institute, 99, 206-214.
96. Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, A., Stein, H., Thiele, J. & Vardiman, J. (2008) Hodgkin Lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. WHO, Geneva.
97. Swerdlow, A.J., Higgins, C.D., Smith, P., Cunningham, D., Hancock, B.W., Horwich, A., Hoskin, P.J., Lister, T.A., Radford, J.A., Rohatiner, A.Z. & Linch, D.C. (2011) Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. Journal of Clinical Oncology, 29, 4096-4104.
98. Tam, C.S., Herschtal, A. & Seymour, J.F. (2011) ABVD versus BEACOPP for Hodgkin's lymphoma. New England Journal of Medicine, 365, 1544-1545; author reply 1546.
99. Taylor, A.J., Winter, D.L., Stiller, C.A., Murphy, M. & Hawkins, M.M. (2007) Risk of breast cancer in female survivors of childhood Hodgkin's disease in Britain: a population-based study. International Journal of Cancer, 120, 384-391.
100. The International ChlVPP Treatment Group (1995) ChlVPP therapy for Hodgkin's disease: experience of 960 patients. The International ChlVPP Treatment Group. Annals of Oncology, 6, 167-172.
101. Townsend, W. & Linch, D. (2012) Hodgkin's lymphoma in adults. Lancet, 380, 836-847.
102. Travis, L.B., Hill, D., Dores, G.M., Gospodarowicz, M., van Leeuwen, F.E., Holowaty, E., Glimelius, B., Andersson, M., Pukkala, E., Lynch, C.F., Pee, D., Smith, S.A., van't Veer, M.B., Joensuu, T., Storm, H., Stovall, M., Boice, J.D. Jr, Gilbert, E. & Gail, M.H. (2005) Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. Journal of the National Cancer Institute, 97, 1428-1437.
103. von Tresckow, B., Plutschow, A., Fuchs, M., Klimm, B., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M.S., Meissner, J., Zijlstra, J.M., Soekler, M., Stein, H., Eich, H.T., Mueller, R.P., Diehl, V., Borchmann, P. & Engert, A. (2012) Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial. Journal of Clinical Oncology, 30, 907-913.
104. Vassilakopoulos, T.P., Angelopoulou, M.K., Siakantaris, M.P., Konstantinou, N., Symeonidis, A., Karmiris, T., Repoussis, P., Roussou, P., Dimopoulos, A.M., Kokoris, S.I., Dimitriadou, E.M., Kyrtsonis, M.C., Dimopoulou, M.N., Tsatalas, C., Kokkinis, G., Vrakidou, E., Grigoraki, V., Poziopoulos, C., Stamatellou, M., Liapis, D., Georgiou, G., Panayiotidis, P. & Pangalis, G.A. (2006) Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease. Haematologica, 91, 32-39.
105. Viviani, S., Zinzani, P.L., Rambaldi, A., Brusamolino, E., Levis, A., Bonfante, V., Vitolo, U., Pulsoni, A., Liberati, A.M., Specchia, G., Valagussa, P., Rossi, A., Zaja, F., Pogliani, E.M., Pregno, P., Gotti, M., Gallamini, A., Rota Scalabrini, D., Bonadonna, G. & Gianni, A.M. (2011) ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. New England Journal of Medicine, 365, 203-212.
106. Voss, S.D., Chen, L., Constine, L.S., Chauvenet, A., Fitzgerald, T.J., Kaste, S.C., Slovis, T. & Schwartz, C.L. (2012) Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. Journal of Clinical Oncology, 30, 2635-2640.
107. Weiler-Sagie, M., Bushelev, O., Epelbaum, R., Dann, E.J., Haim, N., Avivi, I., Ben-Barak, A., Ben-Arie, Y., Bar-Shalom, R. & Israel, O. (2010) (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. Journal of Nuclear Medicine, 51, 25-30.
108. Westlake, S. & Cooper, N. (2008) Cancer incidence and mortality: trends in the United Kingdom and constituent countries, 1993 to 2004. Health Statistics Quarterly, 38, 33-46.
109. Williams, S.D., Birch, R., Einhorn, L.H., Irwin, L., Greco, F.A. & Loehrer, P.J. (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. New England Journal of Medicine, 316, 1435-1440.
110. Wong, M., O'Neill, S., Walsh, G. & Smith, I.E. (2013) Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Annals of Oncology, 24, 133-138.